A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. (Q50330287)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 August 2016

Language	Label	Description	Also known as
English	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.	scientific article published on 10 August 2016

Statements

scholarly article

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. (English)

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

chronic myeloid leukemia

0 references

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

Hagop Kantarjian

2

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

4 March 2018

Gautam Borthakur

11

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

4 March 2018

8

object named as

Tapan Kadia

1 reference

Europe PubMed Central

4 March 2018

7

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

4 March 2018

13

object named as

Elias Jabbour

1 reference

Europe PubMed Central

4 March 2018

Guillermo Garcia-Manero

12

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

4 March 2018

Jorge Eduardo Cortes

14

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

4 March 2018

Naveen Pemmaraju

9

object named as

Naveen Pemmaraju

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

4

object named as

Koji Sasaki

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

10

object named as

Naval Daver

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

6

object named as

Sara DellaSala

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

Koichi Takahashi

1

object named as

Koichi Takahashi

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

author name string

Yulong Yang

3

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

language of work or name

0 references

publication date

10 August 2016

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

122

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

3336-3343

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

21

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

Which TKI? An embarrassment of riches for chronic myeloid leukemia patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

22 May 2018

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

22 May 2018

Selecting an appropriate caliper can be essential for achieving good balance with propensity score matching

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

22 May 2018

Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

22 May 2018

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

22 May 2018

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

22 May 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

22 May 2018

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

22 May 2018

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

22 May 2018

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

22 May 2018

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

22 May 2018

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

22 May 2018

One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

14 August 2018

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

14 August 2018

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

14 August 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

14 August 2018

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

14 August 2018

Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073019

14 August 2018

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30197

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.30197

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5073019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50330287&oldid=1784708397"